How Asia-Pacific Can Solve Clinical Trial Enrollment and Diversity Challenges

As clinical trial recruitment and patient diversity remain major challenges for biotech companies, Asia-Pacific is becoming an increasingly important part of global clinical development strategy.

Moderated by Meredith Landry (Citeline), the session brought together experts from Pacific Bridge NY, Vicero, Expecto Health Sciences, Southern Star Research, and Nucleus Network to discuss how APAC can help sponsors address enrollment and diversity challenges in clinical trials.

The report outlines the clear advantages APAC can offer sponsors, particularly in patient access, recruitment speed, and the ability to support more representative trial populations. It also explores the role of established clinical trial hubs such as Australia, where mature infrastructure, operational expertise, and a favourable business environment create strong conditions for clinical research.

However, the report also highlights the importance of country-level planning across APAC. Regulatory readiness, site maturity, patient trust, standard of care, investigator engagement, and operational capability can vary significantly across and within countries. Sponsors must also consider how cultural, genetic, and healthcare-system differences shape trial design and execution.

For sponsors, this makes regional expertise critical. Experienced CROs and local partners can help navigate country-specific differences, engage the right sites and investigators, and translate APAC’s potential into practical trial delivery while reducing operational and development risk.

To explore the insights shared by Marc Appel, Alison Finger, Pramod Kashid, Lloyd Prescott, and Graham Wood, download the full executive summary for FREE here.